Cytiva, formerly part of GE Healthcare Life Sciences, has launched the first liquid nitrogen-free cryogenic shipment system designed and optimised for the shipment of cellular therapies and cryopreserved apheresis.
The VIA Capsule system comprises a shipper unit, an integrated smart monitor, and a cryocooler. Combined, these provide the conditions and functionality required to ensure cell viability during the entire logistics process from the manufacturer to the patient’s bedside.
Catarina Flyborg, Vice-President of Cytiva Cell and Gene Therapy, said, “Ensuring that cryogenic temperature is maintained from the bench to the bedside is paramount for cellular therapies.”
“The VIA Capsule system reduces many risks, as well as the complexities and inefficiencies, associated with the current shipping methods, to ensure the safe delivery of life-saving therapies.”
Designed by cryobiologists, the VIA Capsule system consists of a Stirling cryocooler which cools the shipper unit prior to transportation and gives extended temporary cryogenic storage when connected to a power source.
Its internal thermal core provides five days of passive standby when disconnected from its power source, with an LCD interface displaying the time remaining at cryogenic temperature and current temperature of the shipment.
The system also features a smart monitor which automatically uploads temperature, condition and location information in real-time to a dashboard in the Chronicle software platform.
Additionally, the system has wheels that allow for easier manoeuvring and delivery in a hospital setting.